CD8A and neoplasm: Using microarrays from formalin-fixed, paraffin-embedded from 45 PDAC short-term survivors (OS < 3 years) and from formalin-fixed, paraffin-embedded from 51 PDAC long-term survivors (OS ≥ 3 years), authors highlighted the fact that tumor ICL2 (TILC2s) were enriched in rare long-term PDAC survivors with “hot” tumors (activated CD8+ T-cell-enriched types) when compared with short-term survivors with “cold” tumors [86].